Elsevier

Blood Reviews

Volume 51, January 2022, 100888
Blood Reviews

Review
Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues

https://doi.org/10.1016/j.blre.2021.100888Get rights and content

Abstract

Hairy cell leukemia (HCL) is an indolent B-cell malignancy, usually driven by the BRAF V600E mutation. For 30 years, untreated and relapsed HCL was successfully treated with purine analogs, but minimal residual disease (MRD) remained in most patients, eventually causing relapse. Repeated purine analogs achieve decreasing efficacy and increasing toxicity, particularly to normal T-cells. MRD-free complete remissions (CRs) are more common using rituximab with purine analogs in both 1st-line and relapsed settings. BRAF inhibitors and Ibrutinib can achieve remission, but due to persistence of MRD, must be used chronically to prevent relapse. BRAF inhibition combined with Rituximab can achieve high MRD-free CR rates. Anti-CD22 recombinant immunotoxin moxetumomab pasudotox is FDA-approved in the relapsed setting and is unique in achieving high MRD-free CR rates as a single-agent. Avoiding chemotherapy and rituximab may be important in ensuring both recovery from COVID-19 and successful COVID-19 vaccination, an area of continued investigation.

Keywords

Hairy cell leukemia
Treatment
Cladribine
Rituximab
Vemurafenib
Dabrafenib
Trametinib
Moxetumomab pasudotox
Minimal residual disease

Cited by (0)

View Abstract